Please assess the completion status of the following clinical trial:

Trial Title: A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Post-pubescent adolescent age 10 to 16 with heterozygous familial hypercholesterolemia~* Agree to use (and/or have their partner use) acceptable methods of birth control beginning at the prestudy visit until at least 2 weeks after dosing of study drug~* Height and weight fall between the 10th and 95th percentile for age with a minimum body weight of 23 kg~* Receiving appropriate medical care for hypercholesterolemia, such as a statin or other lipid-modifying therapy.~Exclusion Criteria:~* History of psychiatric or personality disorders that may affect the patient's ability to participate~* History of stroke, chronic seizures, or major neurological disorder~* History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases (excluding lipid abnormalities)~* Poorly controlled or recently diagnosed Type 1 or Type 2 diabetes mellitus~* History of neoplastic disease within previous 5 years~* Consumes alcohol or excessive amounts of products that contain caffeine (e.g. cola)~* Has had major surgery, donated and/or received blood within previous 8 weeks~* Participated in another investigational study within previous 4 weeks~* History of significant multiple and/or severe allergies (including latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food~* Positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV)~* Cannot swallow large tablets~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- MK-0524A 1 g/20 mg (Panel A) (Type: EXPERIMENTAL): Single oral dose of 1 tablet of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg
- MK-0524A 2 g/40 mg (Panel B) (Type: EXPERIMENTAL): Single oral dose of 2 tablets of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).